OptiBiotix Health (STU:OB3) Total Liabilities: €0.70 Mil (As of Dec. 2025)


What is OptiBiotix Health Total Liabilities?

OptiBiotix Health STU:OB3 +1.39% Total Liabilities is €0.70 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

OptiBiotix Health's Total Liabilities for the quarter that ended in Dec. 2025 was €0.70 Mil.

OptiBiotix Health's quarterly Total Liabilities increased from Dec. 2024 (€0.78 Mil) to Jun. 2025 (€0.86 Mil) but then declined from Jun. 2025 (€0.86 Mil) to Dec. 2025 (€0.70 Mil).

OptiBiotix Health's annual Total Liabilities increased from Dec. 2023 (€0.62 Mil) to Dec. 2024 (€0.78 Mil) but then declined from Dec. 2024 (€0.78 Mil) to Dec. 2025 (€0.70 Mil).

OptiBiotix Health Total Liabilities Historical Data

* Premium members only.

The historical data trend for OptiBiotix Health's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OptiBiotix Health Total Liabilities Chart

OptiBiotix Health Annual Data
Trend Nov15 Nov16 Nov17 Nov18 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.32 0.74 0.62 0.78 0.70

OptiBiotix Health Semi-Annual Data
Nov15 May16 Nov16 May17 Nov17 May18 Nov18 May19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 0.79 0.78 0.86 0.70

OptiBiotix Health Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

OptiBiotix Health's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.439+(0+0.258
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.70

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=7.879-7.182
=0.70

OptiBiotix Health's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.439+(0+0.258
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.70

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=7.879-7.182
=0.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €0.70 Mil mean?
OptiBiotix Health (STU:OB3) has a Total Liabilities of €0.70 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for OptiBiotix Health and its competitors.
Is OptiBiotix Health's Total Liabilities too high?
OptiBiotix Health's current Total Liabilities is €0.70 Mil.
How does OptiBiotix Health's Total Liabilities compare to VRTX and REGN?
OptiBiotix Health's Total Liabilities of €0.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for OptiBiotix Health and its competitors. OptiBiotix Health's current Total Liabilities is €0.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OptiBiotix Health stock overvalued right now?
OptiBiotix Health (STU:OB3) has a current Total Liabilities of €0.70 Mil. The stock's GF Value™ is €0.34, compared to a current price of €0.07 — trading 78.5% below its estimated fair value. The current Total Liabilities is €0.70 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For OptiBiotix Health (STU:OB3), the current Total Liabilities is €0.70 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OptiBiotix Health Business Description

Other Exchanges OPTI:UK
Address Innovation Centre, Innovation Way, Heslington, York, GBR, YO10 5DG
OptiBiotix Health PLC principal activity is that of identifying and developing microbial strains, compounds, and formulations for use in food ingredients, supplements and active compounds that can impact on human physiology, deriving potential health benefits. It is a life sciences business focused on the development of products which reduce hunger and food cravings, enhance the gut microbiome, and provide a healthy substitute for sugar. Its product portfolio includes First-generation products- SlimBiome, WellBiome; and Second-generation solutions- SweetBiotix, Microbiome Modulators. The group has one class of business. It has presence in United Kingdom, United States, India China, and Rest of world. The company generates majority of revenue from United States.